Conor E Steuer1, Opeyemi A Jegede2, Suzanne E Dahlberg3, Heather A Wakelee4, Steven M Keller5, William J Tester6, David R Gandara7, Stephen L Graziano8, Alex A Adjei9, Charles A Butts10, Suresh S Ramalingam11, Joan H Schiller12. 1. Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia. Electronic address: csteuer@emory.edu. 2. Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 3. Boston Children's Hospital, Boston, Massachusetts. 4. Stanford University School of Medicine and Stanford Cancer Institute, Stanford, California. 5. Merck, Kenilworth, New Jersey. 6. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania. 7. University of California Davis Comprehensive Cancer Center, Sacramento, California. 8. State University of New York Upstate Medical University, Syracuse, New York. 9. Mayo Clinic, Rochester, Minnesota. 10. Cross Cancer Institute, Edmonton, Alberta, Canada. 11. Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia. 12. Inova Schar Cancer Institute, Falls Church, Virginia.
Abstract
INTRODUCTION: Smoking cessation has been reported to benefit patients even after a diagnosis of lung cancer. We studied the smoking behavior of patients who participated in a phase 3 trial of adjuvant therapy following resection of stages IB-IIIA NSCLC. METHODS: The ECOG-ACRIN 1505 was conducted to determine whether the addition of bevacizumab to adjuvant chemotherapy would improve overall survival (OS) for patients with early-stage NSCLC. Studying the association between smoking status and OS was a secondary end point. Patients completed a questionnaire on their smoking habits at baseline, 3, 6, 9, and 12 months. RESULTS: A total of 1501 patients were enrolled, and 99.8%, 95%, 94%, 93%, and 93% responded to the questionnaire at baseline, 3, 6, 9, and 12 months, respectively. A total of 90% reported a current or previous history of cigarette smoking. In addition, 60% of nonsmokers at enrollment reported smoking after diagnosis (before randomization); however, 1% of them reported smoking at 12 months. Furthermore, 94% of the respondents smoked none/fewer cigarettes daily at 12 months. The incidence of grades 3-5 toxicity on treatment was 68%, 76%, and 72% in never, former, and current smokers, respectively (p = 0.05). The disease-free survival for never-smokers relative to current and former smokers was (hazard ratio [HR] 0.93, p = 0.64 and HR 1.05, p = 0.72), and OS was (adjusted HR for death 0.54, p = 0.005 and adjusted HR for death 0.68, p = 0.03), respectively. CONCLUSIONS: This is the first comprehensive, prospective report of smoking habits in patients with NSCLC patients from a phase III early-stage trial. There was a high rate of smoking reduction and cessation following study entry. The disease-free survival did not differ significantly between smokers and never smokers, though there were less grade 3-5 toxicities and more favorable OS in never-smokers.
INTRODUCTION: Smoking cessation has been reported to benefit patients even after a diagnosis of lung cancer. We studied the smoking behavior of patients who participated in a phase 3 trial of adjuvant therapy following resection of stages IB-IIIA NSCLC. METHODS: The ECOG-ACRIN 1505 was conducted to determine whether the addition of bevacizumab to adjuvant chemotherapy would improve overall survival (OS) for patients with early-stage NSCLC. Studying the association between smoking status and OS was a secondary end point. Patients completed a questionnaire on their smoking habits at baseline, 3, 6, 9, and 12 months. RESULTS: A total of 1501 patients were enrolled, and 99.8%, 95%, 94%, 93%, and 93% responded to the questionnaire at baseline, 3, 6, 9, and 12 months, respectively. A total of 90% reported a current or previous history of cigarette smoking. In addition, 60% of nonsmokers at enrollment reported smoking after diagnosis (before randomization); however, 1% of them reported smoking at 12 months. Furthermore, 94% of the respondents smoked none/fewer cigarettes daily at 12 months. The incidence of grades 3-5 toxicity on treatment was 68%, 76%, and 72% in never, former, and current smokers, respectively (p = 0.05). The disease-free survival for never-smokers relative to current and former smokers was (hazard ratio [HR] 0.93, p = 0.64 and HR 1.05, p = 0.72), and OS was (adjusted HR for death 0.54, p = 0.005 and adjusted HR for death 0.68, p = 0.03), respectively. CONCLUSIONS: This is the first comprehensive, prospective report of smoking habits in patients with NSCLC patients from a phase III early-stage trial. There was a high rate of smoking reduction and cessation following study entry. The disease-free survival did not differ significantly between smokers and never smokers, though there were less grade 3-5 toxicities and more favorable OS in never-smokers.
Authors: Jonathan M Samet; Erika Avila-Tang; Paolo Boffetta; Lindsay M Hannan; Susan Olivo-Marston; Michael J Thun; Charles M Rudin Journal: Clin Cancer Res Date: 2009-09-15 Impact factor: 12.531
Authors: Yolanda I Garces; Ping Yang; Julia Parkinson; Xinghua Zhao; Jason A Wampfler; Jon O Ebbert; Jeff A Sloan Journal: Chest Date: 2004-12 Impact factor: 9.410
Authors: Relin Yang; Michael C Cheung; Felipe E Pedroso; Margaret M Byrne; Leonidas G Koniaris; Teresa A Zimmers Journal: J Surg Res Date: 2011-05-23 Impact factor: 2.192
Authors: Erica N Peters; Essie Torres; Benjamin A Toll; K Michael Cummings; Ellen R Gritz; Andrew Hyland; Roy S Herbst; James R Marshall; Graham W Warren Journal: J Clin Oncol Date: 2012-06-11 Impact factor: 44.544
Authors: T Fujisawa; T Iizasa; Y Saitoh; Y Sekine; S Motohashi; T Yasukawa; K Shibuya; K Hiroshima; H Ohwada Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Chris T Bolliger; Jean-Pierre Zellweger; Tobias Danielsson; Xandra van Biljon; Annik Robidou; Ake Westin; André P Perruchoud; Urbain Säwe Journal: Nicotine Tob Res Date: 2002-11 Impact factor: 4.244